Prospective, double-blind, randomized clinical trial comparing an ERAS pathway with ketorolac and pregabalin versus standard of care plus placebo during live donor nephrectomy for kidney transplant
Open Access
- 27 December 2018
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 19 (6), 1777-1781
- https://doi.org/10.1111/ajt.15242
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pregabalin reduces postoperative opioid consumption and pain for 1 week after hospital discharge, but does not affect function at 6 weeks or 3 months after total hip arthroplastyBritish Journal of Anaesthesia, 2015
- Gender differences in use of prescription narcotic medications among living kidney donorsClinical Transplantation, 2015
- Building the Case for Enhanced Recovery Protocols in Living Kidney DonorsTransplantation, 2015
- Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind studyInternational Urology and Nephrology, 2014
- A Double-Blind Randomized Controlled Trial of Continuous Intravenous Ketorolac vs Placebo for Adjuvant Pain Control After Renal SurgeryMayo Clinic Proceedings, 2012
- A Novel Injectable Formulation of Diclofenac Compared with Intravenous Ketorolac or Placebo for Acute Moderate-to-Severe Pain After Abdominal or Pelvic SurgeryAnesthesia & Analgesia, 2012
- Pregabalin-Induced HepatotoxicityAnnals of Pharmacotherapy, 2011
- The Doctor's Dilemma: Opiate Analgesics and Chronic PainNeuron, 2011
- Treatment of Pregabalin Toxicity by Hemodialysis in a Patient With Kidney FailureAmerican Journal of Kidney Diseases, 2009
- Parenteral Ketorolac: The Risk for Acute Renal FailureAnnals of Internal Medicine, 1997